GVP Module XVI: Routine and Additional Risk Minimisation Measures

Introduction

Risk minimisation measures (RMM) are interventions intended to prevent or reduce the occurrence of adverse reactions associated with exposure to a medicinal product, or to reduce their severity or impact when they occur. GVP Module XVI places these measures within the wider benefit-risk management cycle and distinguishes between routine risk minimisation and additional risk minimisation measures. citeturn1search21turn1search6

The distinction matters because additional measures are not simply a more elaborate version of routine measures. They are used when routine risk minimisation is not sufficient to address a particular safety concern, and they consequently require additional planning, implementation, coordination and, where applicable, effectiveness evaluation. citeturn1search21

The practical question is therefore not "Does this product have risk minimisation?" Every medicinal product is subject to routine risk minimisation. The more useful questions are what safety concern is being managed, what outcome is intended, why routine measures are or are not sufficient, and what intervention is proportionate to the residual risk?

1. Risk Minimisation Within the Benefit-Risk Cycle

Risk minimisation should not be designed independently of the safety concern. The starting point is the understanding of the risk: its seriousness, severity, preventability, clinical consequences, affected population and circumstances of exposure.

The risk-management process then asks what intervention can alter the probability or consequences of the adverse reaction. The chosen measure should be linked to an intended outcome rather than selected because a particular communication or control tool is familiar.

This creates a logical sequence:

Safety concern
      ↓
Characterisation of the risk
      ↓
Residual risk and preventability
      ↓
Intended outcome
      ↓
Selection of RMM
      ↓
Implementation
      ↓
Evaluation where appropriate
      ↓
Adaptation within the benefit-risk cycle

Module XVI Rev. 3 explicitly strengthens this lifecycle approach, including guidance on intended outcomes, implementation pathways, stakeholder engagement, effectiveness evaluation, adaptation and quality systems. citeturn1search21

2. What Routine Risk Minimisation Means

Routine risk minimisation consists of the measures that apply to medicinal products as part of their normal authorised use and product information framework.

These measures are primarily communicated through the product information and associated regulatory tools. Their purpose is to provide the information and instructions needed for safe use without requiring a separate additional programme for the particular safety concern.

Routine measures therefore form the baseline against which the need for additional measures is considered.

3. Why Routine Measures Usually Come First

The existence of a serious safety concern does not automatically justify an additional risk-minimisation programme.

The organisation should first determine whether the risk can be adequately managed through routine measures. This reflects proportionality: additional controls can introduce complexity, burden healthcare professionals and patients, and create new implementation risks.

An additional measure should therefore have a defined reason for existing beyond the information and controls already provided through routine risk minimisation.

4. Examples of Routine Risk Minimisation

Routine measures can include information in the SmPC and package leaflet, labelling and other elements of the authorised product information. Depending on the product and risk, these can communicate contraindications, warnings, precautions, adverse reactions, dosing instructions, monitoring requirements and other information needed for safe use.

The precise tools available and their regulatory status depend on the applicable product-information framework. Module XVI should therefore be read together with GVP Module V and the applicable pharmaceutical legislation rather than treated as an independent catalogue of every routine tool. citeturn1search21

5. When Additional Risk Minimisation Becomes Relevant

Additional risk minimisation becomes relevant when routine measures are insufficient for a specific safety concern and an intervention beyond routine product information is needed to manage the risk.

The decision should follow from the characteristics of the risk and the clinical action required. Factors include seriousness and severity, preventability, indication, route of administration, target population and healthcare setting. A single safety concern may require more than one measure, while one measure may address more than one concern. citeturn1search21

The important point is that additional describes the relationship with routine measures. It does not mean that the safety concern is necessarily more severe than every other concern associated with the product.

6. Additional Measures Are Targeted Interventions

Additional measures should be designed around a defined safety objective and target population.

For example, if the risk arises from a particular prescribing circumstance, the intervention may need to reach prescribers and influence the relevant clinical decision. If the risk arises from a preparation or administration problem, the measure may need to address the person performing that task.

The intervention should therefore follow the mechanism through which the risk can be prevented or reduced.

7. Educational and Safety-Advice Tools

One category of additional measures consists of educational or safety-advice tools. These are intended to provide information or instructions beyond routine product information where such additional communication is necessary to manage the safety concern. Module XVI Rev. 3 identifies educational/safety-advice tools as a category of additional RMM. citeturn1search21

Examples can include targeted materials for healthcare professionals or patients. The content should focus on the risk-minimisation objective rather than becoming a general information document about the product.

Where educational material is used, the organisation should be able to explain what the recipient is expected to know or do differently after receiving it.

8. Risk Minimisation Control Tools

Additional measures can also involve controls intended to restrict or structure access, prescribing, dispensing, administration or use in order to prevent exposure under circumstances associated with the safety concern.

Module XVI Rev. 3 explicitly distinguishes risk-minimisation control tools from educational/safety-advice tools. citeturn1search21

A control tool should be assessed as part of a system. Adding a control without considering how it will operate in real clinical practice can create workarounds, delays or other unintended effects.

9. Risk Minimisation Control Programmes

Some risks require a coordinated programme rather than a single intervention.

A control programme may combine several measures and define how the target population, healthcare professionals and other participants interact with them. The programme should have clear responsibilities, implementation arrangements and monitoring requirements.

The complexity of a programme should be proportionate to the safety problem. A highly complex programme is not inherently a better programme.

10. The Implementation Pathway

A risk-minimisation measure exists on paper before it exists in clinical practice. Implementation is the process by which the intended intervention becomes available and usable to the target population.

Module XVI Rev. 3 explicitly addresses the implementation pathway. citeturn1search21

A useful implementation model is:

Approved measure
      ↓
Materials / controls available
      ↓
Correct audience reached
      ↓
Audience understands requirement
      ↓
Required action is feasible
      ↓
Action occurs in practice

Failure at any stage can prevent the measure from achieving its safety objective.

11. Development of Materials

Where additional materials are required, development should begin with the intended safety outcome rather than the format of the material.

The content should identify the relevant risk, the circumstances in which it occurs and the action needed to prevent or reduce it. Module XVI Rev. 3 also addresses tailoring materials to target populations, information items and user-testing. citeturn1search21

This makes material development part of risk minimisation rather than merely a publishing exercise.

12. User Testing

A document can be scientifically correct and still fail as a risk-minimisation tool if its intended users misunderstand it.

User-testing can therefore provide evidence about whether the material communicates the required information in a usable way. The purpose is not to make the material attractive for its own sake, but to identify barriers to understanding or correct use.

The level of testing should be proportionate to the role and importance of the material.

13. Engagement of Patients and Healthcare Professionals

Module XVI Rev. 3 gives explicit attention to early engagement of patients and healthcare professionals in risk-minimisation development, dissemination and evaluation. citeturn1search21

Their involvement can identify practical barriers that may not be visible from a purely regulatory or pharmacovigilance perspective. A measure that requires an action unavailable in routine clinical practice cannot be expected to work simply because the instruction is scientifically appropriate.

Engagement is therefore part of designing a workable intervention.

14. Non-Promotional Character

Risk-minimisation material is intended to reduce risk, not to promote use of the medicinal product.

The content should remain focused on the safety concern and intended actions. Module XVI also addresses the non-promotional nature of risk minimisation and personal-data protection. citeturn1search21

This distinction is particularly important when educational materials are distributed through channels that are also used for commercial communication.

15. The Relationship With the RMP

The RMP provides the broader framework for identified risks, potential risks and missing information and for the pharmacovigilance and risk-minimisation activities associated with them.

An additional RMM should therefore have a clear relationship with the relevant safety concern and RMP. The RMP should not simply list a measure without explaining the safety problem and the role the measure is intended to play.

Conversely, the existence of an RMM does not by itself demonstrate that the risk is adequately controlled.

16. One Risk, Multiple Measures

A safety concern may require a combination of measures when no single intervention can address all points in the causal pathway.

For example, routine product information may describe the risk, an educational tool may reinforce recognition of the relevant clinical situation, and a control programme may prevent exposure under a defined circumstance.

The combination should be coherent. Multiple measures that communicate overlapping or inconsistent instructions can increase complexity without improving safety.

17. One Measure, Multiple Risks

The reverse can also occur: a single additional measure may address more than one safety concern.

This can be efficient where the risks share a common prevention mechanism. However, the organisation should ensure that combining objectives does not make the intervention too complicated for its intended users.

The correct unit of design is therefore the risk-minimisation objective, not necessarily the individual document or tool.

18. A Practical Selection Test

Before selecting an additional RMM, the organisation should be able to explain:

1. What safety concern is being addressed?
2. What causes or circumstances make the risk preventable?
3. What action would reduce the risk?
4. Who must perform that action?
5. Why is routine risk minimisation insufficient?
6. Which additional intervention can influence the relevant action?
7. How will implementation be achieved?
8. How will the organisation know whether the intervention is working?

These questions convert the choice of an RMM from a catalogue exercise into a causal design problem.

19. Additional Measures and Clinical Workflow

The effectiveness of an additional measure depends partly on whether it fits the workflow in which the risk occurs.

A prescribing restriction that requires several steps may fail if the information is unavailable at the point of prescribing. A patient card may have limited value if patients are not given it or do not know when to present it. An educational document may not change behaviour if the required action is difficult to perform.

Risk minimisation should therefore be designed around the actual pathway from prescribing or dispensing to exposure and outcome.

20. Example: Preventing Exposure in a Defined Patient Group

Consider a medicinal product associated with a serious risk when used in a particular patient population.

Routine product information may identify the contraindication and explain the risk. If experience shows that this information alone cannot reliably prevent exposure, an additional intervention may be considered.

The additional measure might involve targeted education, a controlled prescribing process or another intervention appropriate to the specific risk. The important point is that the intervention should address the reason the routine measure is insufficient.

This is an illustrative example, not a regulatory finding or a statement that a particular product requires such a measure.

21. Example: A Dosing Error

Suppose a safety concern arises because a product is sometimes administered at the wrong dose due to a complex preparation process.

The risk-minimisation objective is not simply "inform users about the product." It is to reduce incorrect preparation or administration.

The intervention might therefore need to address the concentration, measuring device, preparation instructions or user training. The appropriate measure follows from the mechanism of the error.

22. Example: Recognition of an Important Adverse Reaction

Another safety concern may depend on early recognition of a clinical sign so that treatment can be modified before a serious outcome occurs.

Routine product information may describe the adverse reaction. An additional educational intervention may be appropriate if evidence indicates that healthcare professionals need targeted information about the specific presentation and action required.

The effectiveness question would then concern whether the intended knowledge and clinical behaviour were achieved, rather than whether the material was merely distributed.

23. Example: A Control Programme

A control programme may be appropriate when safe use requires several linked conditions to be satisfied.

For example, the programme could require specified information to be provided to a patient, particular healthcare-professional actions and a controlled dispensing step.

The programme should be analysed as an end-to-end system. If any critical link is unreliable, the apparent presence of the programme may overstate its real-world protection.

24. Avoiding Over-Engineering

Additional risk minimisation can fail through excessive complexity.

Every extra form, registration step, confirmation, communication or restriction creates another opportunity for non-compliance, confusion or workarounds. The objective is not maximum control. It is sufficient control to achieve the safety objective.

A simpler intervention that reliably changes the relevant behaviour may be preferable to a complex programme that is difficult to operate.

25. Avoiding Under-Engineering

The opposite problem is selecting an intervention that cannot plausibly influence the risk.

If the safety concern arises from a decision made at prescribing, a communication sent only after dispensing may have limited preventive value. If the risk depends on correct administration, information delivered to prescribers alone may not address the relevant failure point.

The measure should therefore be mapped to the point at which the risk can actually be prevented or reduced.

26. Dissemination Plans

For additional materials, dissemination is part of implementation rather than an administrative afterthought.

The organisation should understand which audiences must receive the information, through which channels and within what timeframe. Module XVI Rev. 3 specifically addresses dissemination plans and direct healthcare-professional communications. citeturn1search21

A material that exists but does not reach the intended population has not achieved its implementation objective.

27. Direct Healthcare-Professional Communications

A direct healthcare-professional communication may be used when important safety information requires targeted communication and specific action.

The communication should have a defined safety purpose and should remain consistent with the approved regulatory position. Its distribution should be coordinated with other risk-minimisation materials so that healthcare professionals do not receive contradictory instructions.

The applicable EU and national regulatory procedures should be followed for the particular communication.

28. National Implementation

EU-level agreement does not eliminate the practical requirements of implementation in individual Member States.

Languages, healthcare structures, prescribing responsibilities, dispensing arrangements and communication channels can differ. The implementation plan should account for these differences while preserving the underlying safety objective.

A measure should therefore be assessed as implemented only when it is operational in the relevant healthcare setting, not merely when a central document has been approved.

29. Coordination Between MAHs

The same active substance may be present in medicinal products held by multiple marketing authorisation holders.

Where risk minimisation needs to be coordinated across products, inconsistent implementation can weaken the overall intervention and create confusion for healthcare professionals and patients.

Module XVI Rev. 3 specifically addresses coordination of RMM effectiveness evaluation for medicinal products containing the same active substance. citeturn1search21

The regulatory framework determines the applicable coordination arrangements; the operational principle is that the safety objective should not depend on fragmented messages.

30. Additional Measures Are Not Permanent by Definition

An additional RMM should remain connected to the evidence supporting its need.

As the product lifecycle develops, new evidence may show that the risk has changed, that the measure is ineffective, that a different intervention is more appropriate or that the additional measure is no longer necessary.

Module XVI Rev. 3 explicitly provides for adapting risk-minimisation measures within the benefit-risk management cycle. citeturn1search21

31. Adaptation After Effectiveness Evaluation

Effectiveness evaluation should not become a report that sits separately from risk management.

If evidence shows that knowledge is adequate but behaviour has not changed, the intervention may need redesign. If behaviour has changed but the health outcome has not improved, the organisation may need to reconsider whether the measure addresses the correct point in the causal pathway.

The result should feed back into the benefit-risk management cycle.

32. Implementation, Behaviour and Outcome

Module XVI Rev. 3 distinguishes different levels at which effectiveness can be considered, including implementation, behavioural changes and health outcomes. citeturn1search21

These levels answer different questions:

A measure can perform well at one level and poorly at another.

33. Why Distribution Alone Is Insufficient

A distribution record can demonstrate that material was sent. It cannot by itself demonstrate that the recipient read it, understood it, changed behaviour or reduced the relevant risk.

This distinction is central to the revised Module XVI approach. Effectiveness evaluation should be designed around the intended outcome rather than defaulting to measures that are easy to count.

34. Choosing the Evaluation Question

The evaluation question should be defined when the RMM is designed.

If the objective is improved knowledge, a knowledge measure may be appropriate. If the objective is a specific prescribing behaviour, prescribing data or another behavioural measure may be more informative. If the objective is reduction of a clinical outcome, health-outcome data may be required.

The evaluation design should therefore follow the causal chain of the intervention.

35. Mixed Methods

The final Module XVI Addendum II emphasises the value of a mixed-methods approach where appropriate. It provides guidance on quantitative and qualitative data sources and on evaluating knowledge, behavioural and health outcomes. citeturn1search20

Qualitative methods can help explain why a measure did or did not work, while quantitative data can estimate the extent of implementation or behavioural change.

Using both can provide a more complete understanding than relying on a single indicator.

36. Primary and Secondary Data

Effectiveness evaluation may use data generated specifically for the evaluation or existing data collected for another purpose.

The final Addendum II describes both primary and secondary data sources, including healthcare databases, surveys and qualitative approaches. citeturn1search20

The choice should be driven by the question, data quality and feasibility rather than by a preference for a particular study type.

37. A Measure Can Be Implemented but Ineffective

Imagine that an educational programme reaches 95% of the intended healthcare professionals, but the relevant prescribing behaviour changes very little.

The implementation result is strong, but the risk-minimisation objective has not necessarily been achieved.

The next question is why. The message may be unclear, the recommended action may be impractical, the baseline behaviour may be driven by factors outside the intervention, or the measure may not address the principal cause of the risk.

38. A Measure Can Change Behaviour Without Proving a Health Effect

Conversely, a study may demonstrate substantial behavioural change without being able to show a corresponding reduction in a rare clinical outcome.

That does not automatically mean that the measure failed. The outcome may be too uncommon to measure reliably, follow-up may be insufficient, or other factors may influence the outcome.

Interpretation should therefore reflect the hierarchy of intended outcomes and the limitations of the study design.

39. Risk Minimisation and Unintended Consequences

An intervention can introduce effects that were not part of the original safety objective.

A highly restrictive programme may delay access to treatment, discourage appropriate prescribing or impose disproportionate burden on patients and healthcare professionals. These effects should be considered when evaluating the overall intervention.

Risk minimisation is therefore part of benefit-risk management, not a process in which every additional restriction is inherently beneficial.

40. Practical Design Review

Before implementation, the organisation should be able to trace the intervention through the following chain:

Safety concern
      ↓
Preventable mechanism
      ↓
Required action
      ↓
Person who must act
      ↓
Intervention
      ↓
Implementation pathway
      ↓
Expected behaviour
      ↓
Expected outcome
      ↓
Evaluation method

If one of these links is missing, the rationale for the measure may be incomplete.

41. Illustrative Failure Mode: Additional RMM Added Without a Clear Objective

An organisation introduces an educational programme because a safety concern is considered serious, but the programme does not define what knowledge or behaviour should change.

The potential weakness is not that education was necessarily inappropriate. It is that the intervention cannot be meaningfully evaluated because its intended outcome was never specified.

A better design begins with the safety objective and then determines whether education can plausibly influence it.

42. Illustrative Failure Mode: The Measure Reaches the Wrong User

A risk depends on correct administration by a healthcare professional, but the principal additional communication is directed to prescribers who are not involved in administration.

The communication may be scientifically accurate and widely distributed while having little effect on the relevant risk.

The potential weakness is a broken implementation pathway between the intervention and the point at which the risk can be prevented.

43. Illustrative Failure Mode: Implementation Is Confused With Effectiveness

A company documents that educational materials were distributed according to plan and concludes that the additional RMM was effective.

Distribution is evidence of implementation, not necessarily evidence of changed knowledge, behaviour or health outcome.

The appropriate evaluation depends on the objective established for the measure.

44. Illustrative Failure Mode: Complexity Creates Workarounds

A control programme requires several sequential actions and creates significant delays in routine clinical practice. Healthcare professionals begin using informal workarounds.

The potential weakness is not simply non-compliance. The design of the measure may itself have created barriers to correct implementation.

Evaluation should therefore consider usability and unintended consequences as part of the overall risk-minimisation system.

45. Illustrative Failure Mode: Conflicting Materials

A revised risk-minimisation instruction is distributed while older materials remain in circulation. The two versions contain materially different instructions.

The potential weakness is inadequate version control and coordination.

A safety intervention can become less effective when the target population receives multiple competing instructions.

46. Illustrative Failure Mode: A Measure Becomes Permanent by Inertia

An additional measure remains in place for years even though subsequent evidence has changed the understanding of the risk and the measure's effectiveness has not been reassessed.

The potential weakness is treating an RMM as a permanent administrative requirement rather than as an intervention within the benefit-risk lifecycle.

Module XVI Rev. 3 explicitly provides for adaptation of risk-minimisation measures as evidence changes. citeturn1search21

47. Quality Systems for Risk Minimisation

Module XVI Rev. 3 contains a dedicated section on quality systems for risk minimisation. citeturn1search21

This reflects an important principle: a risk-minimisation measure is not effective simply because the scientific concept is sound. The organisation also needs controlled processes for development, approval, dissemination, implementation, monitoring and adaptation.

The quality system should therefore focus on the critical steps that determine whether the intervention can achieve its intended safety outcome.

48. Documentation

The rationale for an additional RMM should be documented sufficiently to show the relationship between the safety concern, intended outcome, selected intervention and evaluation approach.

Implementation records should demonstrate what was done, when, for whom and through which channel. Evaluation records should preserve the methods, data, results, interpretation and resulting decisions.

This allows the organisation to reconstruct the lifecycle of the intervention rather than merely prove that a document existed.

49. Relationship With the PSUR

Relevant information about risk-minimisation measures and their effectiveness may need to feed into aggregate safety evaluation.

The PSUR can provide an opportunity to consider whether new evidence changes the benefit-risk balance or the need for risk-minimisation measures. The organisation should maintain traceability between significant RMM evaluations and subsequent aggregate conclusions where relevant.

50. Relationship With Regulatory Procedures

Additional RMM may be established, modified or removed through applicable regulatory procedures.

The organisation should distinguish the scientific rationale for an intervention from the legal or procedural mechanism through which the measure becomes an authorised requirement.

Implementation should follow the final regulatory position rather than an earlier proposal or draft assessment.

51. Relationship With Safety Communication

Additional RMM often involve communication, but not every safety communication is an additional RMM.

A communication becomes part of risk minimisation when it is designed and used as an intervention to prevent or reduce a defined safety risk. Routine safety information may communicate risks without constituting a separate additional programme.

This distinction matters when defining objectives and evaluating effectiveness.

52. Relationship With Signal Management

A new signal may trigger reconsideration of existing risk-minimisation measures, but signal management and risk minimisation remain distinct processes.

The signal process evaluates emerging evidence. The risk-management process determines how an identified or potential risk should be managed.

A signal may therefore lead to no change, additional monitoring, modification of an existing RMM or introduction of a new measure depending on the evidence and benefit-risk assessment.

53. Embryo-Fetal Risks as a Special Case

GVP Module XVI now contains a final Addendum I specifically addressing risk minimisation measures for medicinal products with embryo-fetal risks. EMA states that the addendum became legally effective on 29 August 2025. citeturn1search22turn1search0

The addendum illustrates how the general principles of Module XVI can be developed for a particular safety problem. It addresses intended actions to prevent exposure, actions following possible exposure, routine and additional tools, pregnancy prevention programmes and effectiveness evaluation. citeturn1search22

The existence of this specialised guidance reinforces the broader principle that the intervention should follow the mechanism of the risk.

54. Pregnancy Prevention Programmes

A pregnancy prevention programme is not simply an educational document. It may combine counselling, pregnancy testing, contraception-related actions, prescribing controls, treatment supervision and other measures depending on the risk and target population.

The appropriate components depend on the product and the embryo-fetal risk. The programme should also avoid creating requirements that unnecessarily compromise access to medically necessary treatment where no suitable alternative exists. citeturn0search14

This is an example of why risk minimisation must be considered as a complete clinical pathway rather than as an isolated communication tool.

55. Effectiveness Evaluation Is an Iterative Process

The current Module XVI framework treats effectiveness evaluation as part of an iterative and prospective process rather than a single end-of-programme exercise. EMA describes the revised approach as including measurement of different elements and regulatory follow-up. citeturn0search15

This means that evaluation can inform adaptation while the measure remains in operation.

The organisation should therefore define in advance what evidence would cause it to maintain, modify, intensify or reconsider the intervention.

56. A Practical Governance Model

The complete relationship can be represented as:

Safety concern
      ↓
Risk characterisation
      ↓
Routine RMM assessed
      ↓
Is routine RMM sufficient?
      ├── Yes → Routine management + monitoring
      │
      └── No
           ↓
      Additional RMM designed
           ↓
      Target population + action defined
           ↓
      Implementation
           ↓
      Effectiveness evaluation
           ↓
      Benefit-risk reassessment
           ↓
      Maintain / adapt / replace / remove

This is the core logic of Module XVI: risk minimisation is a lifecycle intervention embedded within benefit-risk management, not a static list of restrictions.

57. Inspection Perspective

An inspector assessing an additional RMM could reasonably ask whether the organisation can demonstrate the chain from safety concern to intervention and from intervention to outcome.

Relevant evidence may include the RMP, regulatory decisions, design rationale, approved materials, dissemination records, implementation monitoring, effectiveness studies, deviation records and subsequent decisions.

The inspection question is not simply whether the measure exists. It is whether the organisation can demonstrate that the measure is appropriately designed, implemented, evaluated and adapted.

58. Practical Review Questions

For a significant additional RMM, ask:

1. What specific safety concern requires the measure?
2. Why are routine measures insufficient?
3. What risk-minimisation objective is being pursued?
4. What behaviour or clinical action must change?
5. Who must perform that action?
6. Is the measure feasible in the relevant healthcare setting?
7. How will implementation be demonstrated?
8. How will knowledge, behaviour or outcomes be evaluated?
9. What unintended consequences could occur?
10. What evidence would trigger adaptation?
11. How does the measure connect to the RMP and PSUR?
12. Can the complete decision and implementation history be reconstructed?

Key Takeaways

Routine risk minimisation is the baseline system for safe use of medicinal products. Additional risk minimisation is used when routine measures are insufficient for a particular safety concern and a targeted intervention is needed.

The correct additional measure follows from the mechanism of the risk. Educational tools, safety advice, control programmes and other interventions should be selected according to the action required, the person who must act and the point in the clinical pathway where the risk can be prevented or reduced.

Implementation and effectiveness are distinct. A measure can be fully distributed yet fail to change knowledge or behaviour. Conversely, behavioural change may be demonstrated without sufficient evidence of a health-outcome effect. Current Module XVI therefore emphasises prospective, iterative evaluation and adaptation.

The most useful way to understand risk minimisation is as a lifecycle: characterise the risk, define the intended outcome, select the proportionate intervention, implement it, evaluate it and adapt it as evidence changes.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module XVI — Risk minimisation measures, Rev. 3, EMA/204715/2012 Rev. 3, effective 6 August 2024. citeturn1search21turn0search2
2. European Medicines Agency. GVP Module XVI Addendum II — Methods for evaluating effectiveness of risk minimisation measures, EMA/419982/2019, effective 6 August 2024. citeturn1search20
3. European Medicines Agency. GVP Module XVI Addendum I — Risk minimisation measures for medicinal products with embryo-fetal risks, EMA/608947/2021, effective 29 August 2025. citeturn1search22turn0search14
4. European Medicines Agency. GVP Module V — Risk management systems.
5. Directive 2001/83/EC, as amended.
6. Regulation (EC) No 726/2004, as amended.
7. Commission Implementing Regulation (EU) No 520/2012, as amended.

Regulatory Note

This article distinguishes the legal and regulatory framework from recommended operational interpretation. Module XVI Rev. 3 and its final addenda should be consulted for current requirements. Product-specific regulatory decisions, RMP conditions and national implementation requirements may impose additional requirements in individual cases.

The examples and failure modes in this article are illustrative and are not presented as documented regulatory findings.